Build status - In Progress

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation
Recruiting
18 years - 100 years
All
Phase 3
1 participants needed
1 Location

Brief description of study

This study is an extension of Study 233AS101, a Phase 1/2/3 study evaluating the benefit/risk of BIIB067. This study will evaluate the long-term safety, tolerability, PK, PD, biomarker effects, and efficacy of BIIB067
administered to participants with SOD1-ALS.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ALS,Amyotrophic Lateral Sclerosis
  • Age: 18 years - 100 years
  • Gender: All

Must have diagnosis of SOD1-ALS and must have completed the End of Study Visit for either Parts A, B, or C of Study 233AS101 (i.e., were not withdrawn).

Updated on 09 Apr 2026. Study ID: 843380

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center